Venture Data Continues To Haunt The Biotech Landscape
This article was originally published in The Pink Sheet Daily
Executive Summary
Venture firms suffered fundraising woes last year, and a handful of biopharma funds stopped investing. It could get worse.
You may also be interested in...
As VC Investments Rebound In Q2, Skepticism Lingers
A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.
As VC Investments Rebound In Q2, Skepticism Lingers
A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.
Sidestepping the "Washout," SV Life Sciences Closes $523 Million Fund
The dedicated health care fund says it will stick with its formula: half the fund into biopharma, the other half spread among devices, diagnostics, services, and information technology.